STOCK TITAN

Definium Therapeutics (DFTX) director granted RSUs and stock options in equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Definium Therapeutics director Roger Adsett reported equity awards consisting of 3,555 common shares in the form of restricted stock units and 14,620 stock options. The options carry an exercise price of $24.11 per share and expire on June 10, 2036.

Both the RSUs and options vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the issuer’s next annual meeting if it occurs before the first anniversary, subject to his continued service. Following these grants, Adsett holds 3,555 common shares and 14,620 options directly.

Positive

  • None.

Negative

  • None.
Insider Adsett Roger
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 14,620 $0.00 --
Grant/Award Common Shares 3,555 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 14,620 shares (Direct, null); Common Shares — 3,555 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
RSU grant size 3,555 shares Restricted stock units granted to director Roger Adsett
Option grant size 14,620 options Stock options granted to acquire common shares
Option exercise price $24.11 per share Conversion or exercise price for stock options
Option expiration June 10, 2036 Expiration date of stock options
Shares held after grant 3,555 shares Total common shares directly held following RSU award
Options held after grant 14,620 options Total stock options directly held following award
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "24.1100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting financial
"any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Adsett Roger

(Last)(First)(Middle)
C/O DEFINIUM THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, SUITE 8500

(Street)
NEW YORK NEW YORK 10007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares06/11/2026A3,555(1)A$0.003,555D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.1106/11/2026A14,620 (2)06/10/2036Common Shares14,620$014,620D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Mark Sullivan, Attorney-in-Fact for Roger Adsett06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did DFTX director Roger Adsett report on this Form 4?

Roger Adsett reported receiving 3,555 restricted stock units and 14,620 stock options in Definium Therapeutics, Inc. These awards are compensation-related equity grants, not open‑market purchases or sales, and increase his direct equity-based exposure to the company.

How many Definium Therapeutics (DFTX) shares and options does Roger Adsett hold after the Form 4?

After the reported awards, Roger Adsett holds 3,555 common shares and 14,620 stock options directly. The common shares come from restricted stock units, while the options provide the right to buy additional shares at a fixed exercise price.

What are the key terms of Roger Adsett’s stock options in Definium Therapeutics (DFTX)?

Adsett’s stock options cover 14,620 underlying common shares at an exercise price of $24.11 per share and expire on June 10, 2036. The options vest in monthly installments, subject to his continued service with the company.

How do the RSUs granted to Roger Adsett by Definium Therapeutics (DFTX) vest?

The 3,555 RSUs vest as to 1/12 of the underlying shares each month after the grant date. If the next annual meeting occurs before the first anniversary, any remaining unvested RSUs vest immediately before that meeting, assuming continued service.

Are Roger Adsett’s Form 4 transactions in DFTX open‑market buys or sells?

No, the Form 4 shows grant or award acquisitions, not market trades. Both the RSUs and stock options were awarded as compensation, with no purchase price paid for the shares or options at the time of grant.